Immatics N.V. (IMTX)
Stock Price:
$10.28 USD
0.02 (0.19%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $10.40 +0.12 (1.17%) Nov 27, 4:14 PM
Key Info
| Market Cap |
646.70M |
| Revenue (ttm) |
18.45M |
| Net Income (ttm) |
-35.20M |
| Shares Out |
62.91M |
| EPS (ttm) |
-27.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$10.28 |
| Previous Close |
$10.26 |
| Change ($) |
0.02 |
| Change (%) |
0.19% |
| Day's Open |
10.26 |
| Day's Range |
10.26 - 10.41 |
| Day's Volume |
19,701 |
| 52-Week Range |
8.67 - 17.25 |
More Stats
| Market Cap |
646.70M |
| Enterprise Value |
646.06M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
62.91M |
| Float |
n/a |
| EPS (basic) |
-27.12 |
| EPS (diluted) |
-27.12 |
| FCF / Share |
4.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
10.51% |
| Payout Ratio |
n/a |
| Shares Short |
717,931 |
| Short Ratio |
5.46 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
9.51 |
| PS Ratio |
35.05 |
| PB Ratio |
142.13 |
| Revenue |
18.45M |
| Operating Income |
-36.63M |
| Net Income |
-35.20M |
| Free Cash Flow |
68.00M |
| Net Cash |
638,502 |
| Net Cash / Share |
0.01 |
| Gross Margin |
100.00% |
| Operating Margin |
-198.54% |
| Profit Margin |
-190.80% |
| FCF Margin |
368.58% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-38.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.01*
(75.18% upside)
Low
13.1
Current: $10.28
High
28.4
Target: 18.01
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 18.45 | 3.77 |
| Revenue Growth | 389.36% | - |
| Gross Profit | 18.45 | 3.77 |
| Operating Income | -33.01 | -34.41 |
| Net Income | -31.57 | -31.44 |
| Shares Outstanding | 1.16 | 1.16 |
| Earnings Per Share | -27.13 | -27.02 |
| Operating Cash Flow | 68.05 | 7.58 |
| Capital Expenditures | -2.14 | -0.41 |
| Free Cash Flow | 65.91 | 7.17 |
| Cash & Equivalents | 103 | 39.37 |
| Total Debt | 3.23 | - |
| Net Cash / Debt | 100 | 39.37 |
| Assets | 134 | 61.32 |
| Liabilities | 175 | 70.49 |
| Book Value | -41.86 | -10.41 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immatics N.V. |
| Country |
Germany |
| Employees |
220 |
| CEO |
Harpreet Singh-Jasuja |
Stock Information
| Ticker Symbol |
IMTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMTX |
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.